Eli Lilly stock rises on Nimbus obesity pill pact as oral drug race heats up

Eli Lilly and Company shares closed up 0.53% at $1,080.36 on Friday and were down 0.17% in after-hours trading at $1,078.50.

Shares of Eli Lilly and Company rose about 0.5% in after-hours trading on Friday, last at $1,080.36. The stock swung between $1,052.96 and $1,080.49 during the regular session.

Drugmakers plan to raise U.S. list prices on at least 350 branded medicines in 2026, according to data from healthcare research firm 3 Axis Advisors. The median increase is about 4%, and the figures do not reflect rebates or other discounts. The same dataset showed drugmakers also plan to cut list prices on about nine medicines, including a more than 40% reduction for diabetes drug Jardiance, sold by Boehringer Ingelheim and Eli Lilly, after Medicare negotiated a lower price for 2026. Reuters

Eli Lilly shares slipped 0.5% in Wednesday’s final session of 2025, closing at $1,074.68, before U.S. markets shut for the New Year’s Day holiday. StockAnalysis+1

Shares of Eli Lilly and Company were up 0.2% at $1,078.73 in after-hours trading on Monday. The stock traded between $1,074.80 and $1,085.12 and about 1.64 million shares had changed hands.

Eli Lilly shares ended the holiday week little changed after South Korean biotech ABL Bio said it would receive $55 million in funding from the U.S. drugmaker under a research collaboration. PR Newswire